# Trial of Pemetrexed Versus Erlotinib in Pretreated Patients With Non Small Cell Lung Cancer (NSCLC)

> **NCT00440414** · PHASE3 · COMPLETED · sponsor: **Hellenic Oncology Research Group** · enrollment: 320 (estimated)

## Conditions studied

- Non Small Cell Lung Cancer

## Interventions

- **DRUG:** Erlotinib (Tarceva)
- **DRUG:** Pemetrexed (Alimta)

## Key facts

- **NCT ID:** NCT00440414
- **Lead sponsor:** Hellenic Oncology Research Group
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-04
- **Primary completion:** 2010-04
- **Final completion:** 2010-04
- **Target enrollment:** 320 (ESTIMATED)
- **Last updated:** 2010-08-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00440414

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00440414, "Trial of Pemetrexed Versus Erlotinib in Pretreated Patients With Non Small Cell Lung Cancer (NSCLC)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00440414. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*